Xencor, Inc. (XNCR)
NASDAQ: XNCR · IEX Real-Time Price · USD
18.26
-0.76 (-4.00%)
Jul 2, 2024, 4:00 PM EDT - Market closed
Xencor Revenue
Xencor had revenue of $162.18M in the twelve months ending March 31, 2024, with 65.41% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $12.81M, a -32.47% decrease year-over-year. In the year 2023, Xencor had annual revenue of $168.34M with 2.28% growth.
Revenue (ttm)
$162.18M
Revenue Growth
+65.41%
P/S Ratio
6.94
Revenue / Employee
$579,218
Employees
280
Market Cap
1.13B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 168.34M | 3.76M | 2.28% |
Dec 31, 2022 | 164.58M | -110.53M | -40.18% |
Dec 31, 2021 | 275.11M | 152.42M | 124.23% |
Dec 31, 2020 | 122.69M | -34.01M | -21.70% |
Dec 31, 2019 | 156.70M | 116.10M | 285.93% |
Dec 31, 2018 | 40.60M | -5.55M | -12.02% |
Dec 31, 2017 | 46.15M | -62.87M | -57.67% |
Dec 31, 2016 | 109.02M | 81.26M | 292.70% |
Dec 31, 2015 | 27.76M | 18.24M | 191.62% |
Dec 31, 2014 | 9.52M | -652.00K | -6.41% |
Dec 31, 2013 | 10.17M | 648.00K | 6.80% |
Dec 31, 2012 | 9.52M | 2.68M | 39.06% |
Dec 31, 2011 | 6.85M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AtriCure | 414.60M |
Prothena Corporation | 89.25M |
Immatics | 80.95M |
Vir Biotechnology | 79.60M |
4D Molecular Therapeutics | 20.45M |
Spyre Therapeutics | 688.00K |
XNCR News
- 19 days ago - Xencor Regains CD20 x CD3 Bispecific T-Cell Engager - Business Wire
- 7 weeks ago - Xencor Reports First Quarter 2024 Financial Results - Business Wire
- 3 months ago - Xencor Appoints Bart Cornelissen as Chief Financial Officer - Business Wire
- 4 months ago - Xencor to Present at Upcoming Investor Conferences - Business Wire
- 4 months ago - Xencor Reports Fourth Quarter and Full Year 2023 Financial Results - Business Wire
- 4 months ago - Xencor to Host Webcast to Review Fourth Quarter and Full Year 2023 Financial Results and Provide Vudalimab Clinical Update - Business Wire
- 6 months ago - Xencor to Present at the 42nd Annual J.P. Morgan Healthcare Conference - Business Wire
- 6 months ago - Dane Leone Joins Xencor as Senior Vice President, Corporate Strategy - Business Wire